Trial Profile
A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cisplatin; Docetaxel; Fluorouracil
- Indications Anal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms SCARCE; SCARCE GERCOR
- 08 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 26 Sep 2023 Planned End Date changed from 1 Jun 2022 to 1 Dec 2023.
- 26 Sep 2023 Status changed from recruiting to active, no longer recruiting.